StockDuty ← Dashboard Oct 20, 2026 04:22 PM ET
CatalystFDA/Bio

Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug

Analysts cheered ARC-20 platform data for the kidney cancer drug, driving Arcus shares up.

What changed
Analysts cheered ARC-20 platform data for the kidney cancer drug, driving Arcus shares up.
Why it matters
Analysts cheered ARC-20 platform data for the kidney cancer drug, driving Arcus shares up. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →